These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Association between apolipoprotein B EcoRI polymorphisms and coronary heart disease : A meta-analysis.
    Author: Chen Y, Zeng J, Tan Y, Feng M, Qin J, Lin M, Zhao X, Zhao X, Liang Y, Zhang N, Rao S.
    Journal: Wien Klin Wochenschr; 2016 Dec; 128(23-24):890-897. PubMed ID: 27637205.
    Abstract:
    OBJECTIVE: The study was carried out to examine the association between apolipoprotein B (ApoB) EcoRI polymorphism (E- vs. E+) (rs1042031) and coronary heart disease (CHD) risk by systematically analyzing multiple independent studies. METHODS: The Hardy-Weinberg equilibrium (HWE) test was applied to assess genotype frequency distribution in healthy controls. The quality of the studies was assessed using the Newcastle-Ottawa scale (NOS). Power analysis was performed with Power and Precision V4 software. A fixed effect model was used because no deviation from homogeneity was found. Publication bias was quantified and examined with Begg's funnel plot test and Egger's linear regression method. The meta-analysis was performed by Stata 12.0 software. RESULTS: A total of 21 eligible association studies were merged in this meta-analysis and the pooled sample consisted of 2994 CHD patients and 3258 healthy controls. No significant publication bias and heterogeneity were observed in these studies. The pooled odds ratio (OR) and 95% confidence interval (CI) of E- vs. E+ were 1.18 (1.06-1.32). The pooled OR (95% CI) of E+ E- + E- E- vs. E+ E+ was 1.18 (1.04-1.34). CONCLUSIONS: This meta-analysis indicated that ApoB EcoRI confers a moderate risk for CHD and the E- allele at this locus might be a susceptibility allele for the development of CHD.
    [Abstract] [Full Text] [Related] [New Search]